Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2016; 7(20): 599-604
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.599
Place of technosphere inhaled insulin in treatment of diabetes
Nasser Mikhail
Nasser Mikhail, Department of Medicine, OliveView-UCLA Medical Center, Sylmar, CA 91342, United States
Author contributions: Mikhail N solely contributed to this paper.
Conflict-of-interest statement: The author has no conflict of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Nasser Mikhail, MD, Department of Medicine, OliveView-UCLA Medical Center, 14445 Olive View Dr, Sylmar, CA 91342, United States. nmikhail@dhs.lacounty.gov
Telephone: +1-818-3643205 Fax: +1-818-3644573
Received: July 19, 2016
Peer-review started: July 21, 2016
First decision: September 5, 2016
Revised: September 20, 2016
Accepted: October 17, 2016
Article in press: October 18, 2016
Published online: December 15, 2016
Processing time: 143 Days and 6.8 Hours
Core Tip

Core tip: Technosphere insulin is the only approved form of inhaled insulin. It is a short-acting insulin that can be taken with meals in patients with type 1 or type 2 diabetes. In this minireview, the author provides an appraisal of this new formulation of insulin to help determine its place in the management of diabetes.